Matches in SemOpenAlex for { <https://semopenalex.org/work/W2809859880> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2809859880 abstract "Introduction Since the discovery and clinical success of the platinum(II) anticancer drug, cisplatin, researchers are putting much effort to develop more efficient metal-based therapeutic compounds, with fewer side-effects and greater cytoselectivity. Ruthenium complexes arose as promising anticancer agents, due to the success of some ruthenium drug candidates in clinical trials. Here we report comparison of in vitro cytotoxic activity and mechanisms of action of cisplatin and four newly synthesised ruthenium(III) complexes with bidentate anionic schiff base derived from 5-methylsalicilaldehyde and methylamine: ( complexes 1– 4 ). Material and methods Cytotoxicity was tested on four human cancer cell lines (K562, A549, EA.hy926, MDA-MB231) and one human non-tumour cell line (MRC-5), by MTT assay. Being the most cytotoxic of all four tested complexes, complex 1 ( C1 ) (Na[RuLCl 2 ], L=N-propyl-5-chlorosalicideniminato) is selected for further analyses of molecular mechanisms underlying its activity toward MDA-MB231 cells. Results and discussions The average IC 50 values were in the low micromolar range 2–23 µM, depending on cell line. Investigated complexes displayed an apparent cytoselective profile, as they reduced the viability of tested tumour cell lines more efficiently than of the non-tumour MRC-5 cells. Cisplatin resistant MDA-MB231 cells showed to be ten times more sensitive to C1 (IC 50 =2 µM) than to cisplatin. 24 hour treatment of MDA-MB231 cells with IC 50 values of C1 and cisplatin induced minor cell cycle alterations, while 48 hour treatment induced substantial accumulation of cells in Sub-G1 region, up to 22.4% ( C1 ) and 86.4% (cisplatin), versus control 4.8%. Acridine orange/ethidium bromide dual staining confirmed the Annexin V-FITC/PI assay results of notable reduction in cell number after the treatment with C1 and cisplatin. While cisplatin-treated cells prominently die of necrosis, C1 -treated cells after 24 hour treatment show apoptotic morphology, but after prolonged treatment, necrosis becomes predominant. Decrease in the intracellular levels of reactive oxygen species was comparable in the cisplatin-treated and C1 -treated cells, with cisplatin displaying more conspicuous effects at higher dose. C1 entered the cells more efficiently compared to cisplatin. Intracellular C1 concentration after 4 hour treatment exceeded that of cisplatin by 7.8 times approximately. Conclusion Present study pointed out interesting activity of this type of ruthenium(III) complex and need for further biological studies and its chemical structure optimisation." @default.
- W2809859880 created "2018-07-10" @default.
- W2809859880 creator A5013342200 @default.
- W2809859880 creator A5046892129 @default.
- W2809859880 creator A5067051468 @default.
- W2809859880 creator A5072430373 @default.
- W2809859880 creator A5088505262 @default.
- W2809859880 date "2018-06-01" @default.
- W2809859880 modified "2023-09-27" @default.
- W2809859880 title "PO-404 Cisplatin and ruthenium(III) complexes – comparison of cellular response of treated MDA-MB231 breast cells" @default.
- W2809859880 doi "https://doi.org/10.1136/esmoopen-2018-eacr25.430" @default.
- W2809859880 hasPublicationYear "2018" @default.
- W2809859880 type Work @default.
- W2809859880 sameAs 2809859880 @default.
- W2809859880 citedByCount "0" @default.
- W2809859880 crossrefType "journal-article" @default.
- W2809859880 hasAuthorship W2809859880A5013342200 @default.
- W2809859880 hasAuthorship W2809859880A5046892129 @default.
- W2809859880 hasAuthorship W2809859880A5067051468 @default.
- W2809859880 hasAuthorship W2809859880A5072430373 @default.
- W2809859880 hasAuthorship W2809859880A5088505262 @default.
- W2809859880 hasBestOaLocation W28098598801 @default.
- W2809859880 hasConcept C109316439 @default.
- W2809859880 hasConcept C126322002 @default.
- W2809859880 hasConcept C154317977 @default.
- W2809859880 hasConcept C161790260 @default.
- W2809859880 hasConcept C185592680 @default.
- W2809859880 hasConcept C202751555 @default.
- W2809859880 hasConcept C2776694085 @default.
- W2809859880 hasConcept C2778239845 @default.
- W2809859880 hasConcept C502942594 @default.
- W2809859880 hasConcept C54355233 @default.
- W2809859880 hasConcept C55493867 @default.
- W2809859880 hasConcept C555196967 @default.
- W2809859880 hasConcept C71924100 @default.
- W2809859880 hasConcept C81885089 @default.
- W2809859880 hasConcept C86803240 @default.
- W2809859880 hasConcept C98274493 @default.
- W2809859880 hasConceptScore W2809859880C109316439 @default.
- W2809859880 hasConceptScore W2809859880C126322002 @default.
- W2809859880 hasConceptScore W2809859880C154317977 @default.
- W2809859880 hasConceptScore W2809859880C161790260 @default.
- W2809859880 hasConceptScore W2809859880C185592680 @default.
- W2809859880 hasConceptScore W2809859880C202751555 @default.
- W2809859880 hasConceptScore W2809859880C2776694085 @default.
- W2809859880 hasConceptScore W2809859880C2778239845 @default.
- W2809859880 hasConceptScore W2809859880C502942594 @default.
- W2809859880 hasConceptScore W2809859880C54355233 @default.
- W2809859880 hasConceptScore W2809859880C55493867 @default.
- W2809859880 hasConceptScore W2809859880C555196967 @default.
- W2809859880 hasConceptScore W2809859880C71924100 @default.
- W2809859880 hasConceptScore W2809859880C81885089 @default.
- W2809859880 hasConceptScore W2809859880C86803240 @default.
- W2809859880 hasConceptScore W2809859880C98274493 @default.
- W2809859880 hasLocation W28098598801 @default.
- W2809859880 hasOpenAccess W2809859880 @default.
- W2809859880 hasPrimaryLocation W28098598801 @default.
- W2809859880 hasRelatedWork W1977078063 @default.
- W2809859880 hasRelatedWork W1987437563 @default.
- W2809859880 hasRelatedWork W2013399883 @default.
- W2809859880 hasRelatedWork W2014419438 @default.
- W2809859880 hasRelatedWork W2016560934 @default.
- W2809859880 hasRelatedWork W2064353919 @default.
- W2809859880 hasRelatedWork W2069310696 @default.
- W2809859880 hasRelatedWork W2134859089 @default.
- W2809859880 hasRelatedWork W2264268250 @default.
- W2809859880 hasRelatedWork W2265771862 @default.
- W2809859880 hasRelatedWork W2321341047 @default.
- W2809859880 hasRelatedWork W2399968889 @default.
- W2809859880 hasRelatedWork W2411109058 @default.
- W2809859880 hasRelatedWork W2411644321 @default.
- W2809859880 hasRelatedWork W2774160470 @default.
- W2809859880 hasRelatedWork W2782874482 @default.
- W2809859880 hasRelatedWork W2898784062 @default.
- W2809859880 hasRelatedWork W2911532461 @default.
- W2809859880 hasRelatedWork W3031844692 @default.
- W2809859880 hasRelatedWork W2765211159 @default.
- W2809859880 isParatext "false" @default.
- W2809859880 isRetracted "false" @default.
- W2809859880 magId "2809859880" @default.
- W2809859880 workType "article" @default.